Citations

Clear

4610 citation(s) found for "Lu, Brian".

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
Kasamon, Yvette L. , Jacene, Heather A. , Gocke, Christopher D. , Swinnen, Lode J., Gladstone, Douglas E. , Perkins, Brandy, Link, Brian K. , Popplewell, Leslie , Herman, Joseph M. , Matsui, William , Jones, Richard J. , Ambinder, Richard F. , Habermann, Thomas M. , Link, Brian K , Ambinder, Richard F

Mayo Clinic

Blood | February 17, 2012 | Volume: 119 | Issue: 18 | Pages: 4129-4132

10.1182/blood-2012-01-402792 | PMID 22343727 Get It

Abstract In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20+ Hodgkin and Reed-Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% for AVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV+ tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as NCT00369681.
Solitary sclerosis
Schmalstieg, William F., Weinshenker, Brian G. , Keegan, B. Mark , Weinshenker, Brian G

Mayo Clinic

Neurology | February 9, 2012 | Volume: 78 | Issue: 8 | Pages: 540-544

10.1212/wnl.0b013e318247cc8c | PMID 22323754 Get It

Factors Associated with Revision Adenoidectomy
Dearking, Amy C., Lahr, Brian D. , Kuchena, Admire, Orvidas, Laura J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 3, 2012 | Volume: 146 | Issue: 6 | Pages: 984-990

10.1177/0194599811435971 | PMID 22301106 Get It

ObjectiveTo determine whether patient factors (eg, indication for initial surgery, medical comorbidity, or age) are associated with adenoid regrowth and subsequent need for revision adenoidectomy and whether surgical factors (eg, surgical technique or level of surgeon’s training) are associated with adenoid regrowth and subsequent need for revision adenoidectomy.Study DesignHistorical cohort study.SettingTertiary care academic medical center.Subjects and MethodsChildren (≤18 years) who underwent adenoidectomy or adenotonsillectomy between 1980 and May 2009 were identified. Medical and surgical records were reviewed for sex, age at surgery, indication for surgery, training level of surgeon, surgical technique, and history of allergies, asthma, or gastroesophageal reflux disease.ResultsOf 8245 surgical cases (53.8% male), 163 were revision adenoidectomies. Age at initial adenoidectomy was a significant factor for revision adenoidectomy, with younger ages associated with higher increased risk. Indication for adenoidectomy was also a significant risk factor; adjusted for age, patients with ear rather than infectious indications were about 10 times more likely to require revision. A diagnosis of gastroesophageal reflux disease was a significant risk factor (hazard ratio, 2.23; P =. 002).ConclusionSeveral risk factors are associated with revision adenoidectomy: young age at initial procedure, indication for adenoidectomy, and diagnosis of gastroesophageal reflux disease. Surgical technique, level of experience of the initial surgeon, and diagnosis of asthma or allergies were not significant risk factors for revision adenoidectomy.
IMWG consensus on maintenance therapy in multiple myeloma
Durie, Brian G.M. , Palumbo, Antonio , Miguel, Jesús F. San , Barlogie, B, Morgan, Gareth J. , Sonneveld, Pieter , Spencer, Andrew , Andersen, Kenneth C., Stewart, Keith, Mateos, María‐Victoria , Wijermans, Pierre W., Waage, Anders , Beksaç, Meral , Richardson, Paul G. , Hulin, Cyrille, Niesvizky, Rubén, Lokhorst, Henk M., Bergsagel, P. Leif , Orlowski, Robert Z. , Hinke, Axel , Cavo, Michèle , Bergsagel, P. Leif , Ludwig, Heinz , McCarthy, Philip L. , Facon, Thierry T.F. , Einsele, Hermann , Richardson, Paul Gerard Guy , Landgren, Ola , Orlowski, Robert Z. , Attal, Michel , San-Miguel, Jesus , Morgan, Gareth J , Beksac, Meral

Mayo Clinic

Blood | January 24, 2012 | Volume: 119 | Issue: 13 | Pages: 3003-3015

10.1182/blood-2011-11-374249 | PMID 22271445 Get It

Abstract Maintaining results of successful induction therapy is an important goal in multiple myeloma. Here, members of the International Myeloma Working Group review the relevant data. Thalidomide maintenance therapy after autologous stem cell transplantation improved the quality of response and increased progression-free survival (PFS) significantly in all 6 studies and overall survival (OS) in 3 of them. In elderly patients, 2 trials showed a significant prolongation of PFS, but no improvement in OS. A meta-analysis revealed a significant risk reduction for PFS/event-free survival and death. The role of thalidomide maintenance after melphalan, prednisone, and thalidomide is not well established. Two trials with lenalidomide maintenance treatment after autologous stem cell transplantation and one study after conventional melphalan, prednisone, and lenalidomide induction therapy showed a significant risk reduction for PFS and an increase in OS in one of the transplant trials. Maintenance therapy with single-agent bortezomib or in combination with thalidomide or prednisone has been studied. One trial revealed a significantly increased OS with a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction and thalidomide maintenance treatment. Maintenance treatment can be associated with significant side effects, and none of the drugs evaluated is approved for maintenance therapy. Treatment decisions for individual patients must balance potential benefits and risks carefully, as a widely agreed-on standard is not established.
Long-term tumor control and cranial nerve outcomes following Gamma Knife surgery for larger-volume vestibular schwannomas
Milligan, Brian D., Pollock, Bruce E. , Foote, Robert L. , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | December 16, 2011 | Volume: 116 | Issue: 3 | Pages: 598-604

10.3171/2011.11.jns11811 | PMID 22175724 Get It

Object Gamma Knife surgery (GKS) for vestibular schwannoma (VS) is an accepted treatment for small- to medium-sized tumors, generally smaller than 2.5 cm in the maximum posterior fossa dimension. The purpose of this study was to evaluate the efficacy and toxicity of GKS for larger tumors. Methods Prospectively collected data were analyzed for 22 patients who had undergone GKS for VSs larger than 2.5 cm in the posterior fossa diameter between 1997 and 2006. No patient had symptomatic brainstem compression at the time of GKS. The median treated tumor volume was 9.4 cm3 (range 5.3–19.1 cm3). The median maximum posterior fossa diameter was 2.8 cm (range 2.5–3.8 cm). The median tumor margin dose was 12 Gy (range 12–14 Gy). Serial imaging, audiometry (10 patients with serviceable hearing pre-GKS), and clinical follow-up were available for a median of 66 months (range 26–121 months). Tumor control failure was defined as either a progressive increase in tumor diameter of at least 2 mm in any dimension or a later resection. Results Four patients met the criteria for GKS failure, including 1 patient who demonstrated sarcomatous degeneration more than 7 years after GKS and died 3 months after microsurgical debulking. An enlarging cystic component was the surgical indication in 1 of the 2 patients who required resection, although 27% of tumors (6 lesions) were cystic before GKS. The 3-year actuarial rate of tumor control, freedom from new facial neuropathy, and preservation of functional hearing were 86%, 92%, and 47%, respectively. At 5 years post-GKS, these rates decreased to 82%, 85%, and 28%, respectively. At the most recent follow-up, 91% of tumors were smaller than at the time of GKS and the median maximum posterior fossa diameter reduction was 26%. On multivariate analysis, none of the following factors was associated with GKS failure, new facial weakness, new trigeminal neuropathy, or loss of serviceable hearing: patient age, tumor volume, tumor margin dose, and preoperative cranial nerve dysfunction. Conclusions Single-session radiosurgery is a successful treatment for the majority of patients with larger VSs. Although tumor control rates are lower than those for smaller VSs managed with GKS, the cranial nerve morbidity of GKS is significantly lower than that typically achieved via resection of larger VSs.
Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: [RETIRED]
Scott, Thomas F. , Frohman, Elliott, Sèze, de , Gronseth, Gary , Weinshenker, Brian G. , Seze, Jerome De , Weinshenker, Brian G

Mayo Clinic

Neurology | December 8, 2011 | Volume: 77 | Issue: 24 | Pages: 2128-2134

10.1212/wnl.0b013e31823dc535 | PMID 22156988 Get It

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease
Wingerchuk, Dean M. , Weinshenker, Brian G. , Weinshenker, Brian G

Mayo Clinic

Multiple Sclerosis Journal | December 6, 2011 | Volume: 18 | Issue: 1 | Pages: 5-10

10.1177/1352458511431077 | PMID 22146604 Get It

Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) are associated with autoantibodies that target aquaporin-4 and, in many cases, multiple other autoantibodies, including antinuclear antibody and antibodies to extractable nuclear antigens. The clinical syndromes that define NMO and NMOSD, especially longitudinally extensive transverse myelitis and optic neuritis, can also occur in the context of established rheumatologic diseases such as systemic lupus erythematosus and Sjögren syndrome and other organ-specific autoimmune diseases. These observations raise questions fundamental to both clinical practice and etiologic research. For example, they could suggest that NMO is one manifestation of a genetic tendency toward humoral autoimmunity. Alternatively, they might indicate that NMO is a central nervous system complication of a multisystem rheumatologic disease. We describe the historical background of this controversy, summarize the current evidence that addresses NMO–systemic autoimmunity relationships, and discuss the practical implications for clinical management.
Global TravEpiNet: A National Consortium of Clinics Providing Care to International Travelers—Analysis of Demographic Characteristics, Travel Destinations, and Pretravel Healthcare of High-Risk US International Travelers, 2009–2011
LaRocque, Regina C. , Rao, Sowmya R. , Ansdell, Vernon, Yates, Johnnie, Schwartz, Brian S. , Knouse, Mark, Cahill, John D. , Hagmann, Stefan , Vinetz, Joseph M. , Connor, Bradley A., Goad, Jeffery A. , Oladele, Alawode, Álvarez, Salvador, Stauffer, William M. , Walker, Patricia F., Kozarsky, Phyllis E., Franco‐Paredes, Carlos , Dismukes, Roberta, Rosen, Jessica , Hynes, Noreen A. , Jacquérioz, Frédérique , McLellan, Susan , Hale, DeVon C., Sofarelli, Theresa A., Schoenfeld, David , Marano, Nina , Brunette, Gary W., Jentes, Emily S. , Yanni, Emad , Sotir, Mark J., Ryan, Edward T. , Lee, Jennifer

Mayo Clinic

Clinical Infectious Diseases | December 6, 2011 | Volume: 54 | Issue: 4 | Pages: 455-462

10.1093/cid/cir839 | PMID 22144534 Get It

Surgical Outcomes for Intractable Epilepsy in Children With Epileptic Spasms
Moseley, Brian D. , Nickels, Katherine , Wirrell, Elaine , Nickels, Katherine C

Mayo Clinic

Journal of Child Neurology | November 29, 2011 | Volume: 27 | Issue: 6 | Pages: 713-720

10.1177/0883073811424463 | PMID 22123426 Get It

Epileptic spasms, or seizures marked by flexor, extensor, or flexor-extensor spasms, are not always responsive to medical management. The purpose of our study was to evaluate the outcome of epilepsy surgery in children with medically intractable epileptic spasms. We identified 11 children with epileptic spasms who underwent lesionectomy (36%), lobectomy (27%), multi-lobectomy (9%), hemispherectomy (18%), or corpus callosotomy (9%). At the time of surgery, 6 children had developed other concurrent seizure type(s), including simple partial (9%), complex partial (27%), partial undifferentiated (9%), primary generalized tonic clonic (9%), tonic (9%), atonic (27%), and myoclonic (9%) seizures. Six children (55%) were seizure free at last follow-up from initial surgery. Predictors of favorable outcome included lack of focal slowing and the presence of less than 2 interictal epileptiform abnormalities on postoperative electroencephalogram ( P = .035 and .035, respectively). Favorable outcome was significantly associated with parent/caregiver report of improved postoperative developmental outcomes ( P = .026).
A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32
Li, Dalin , Best, Timothy, Berg, David J. Van Den, Gourraud, Pierre‐Antoine , Cortessis, Victoria K. , Skol, Andrew D. , Mack, Thomas M. , Glaser, Sally L. , Weiss, Lawrence M. , Nathwani, Bharat N., Schumacher, Fredrick R. , Edlund, Christopher K., Hwang, Amie E. , Fredericksen, Zachary S., Strong, Louise C. , Link, Brian K. , Cerhan, James R. , Conti, David V. , Onel, Kenan , Cozen, Wendy , Bhatia, Ravi , Slager, Susan L. , Habermann, Thomas M. , Robison, Leslie L. , Cerhan, James R , Link, Brian K , Conti, David V

Mayo Clinic

Blood | November 16, 2011 | Volume: 119 | Issue: 2 | Pages: 469-475

10.1182/blood-2011-03-343921 | PMID 22086417 Get It

Nodular sclerosing Hodgkin lymphoma (NSHL) is a distinct, highly heritable Hodgkin lymphoma subtype. We undertook a genome-wide meta-analysis of 393 European-origin adolescent/young adult NSHL patients and 3315 controls using the Illumina Human610-Quad Beadchip and Affymetrix Genome-Wide Human SNP Array 6.0. We identified 3 single nucleotide polymorphisms (SNPs) on chromosome 6p21.32 that were significantly associated with NSHL risk: rs9268542 (P = 5.35 × 10−10), rs204999 (P = 1.44 × 10−9), and rs2858870 (P = 1.69 × 10−8). We also confirmed a previously reported association in the same region, rs6903608 (P = 3.52 × 10−10). rs204999 and rs2858870 were weakly correlated (r2 = 0.257), and the remaining pairs of SNPs were not correlated (r2 < 0.1). In an independent set of 113 NSHL cases and 214 controls, 2 SNPs were significantly associated with NSHL and a third showed a comparable odds ratio (OR). These SNPs are found on 2 haplotypes associated with NSHL risk (rs204999-rs9268528-rs9268542-rs6903608-rs2858870; AGGCT, OR = 1.7, P = 1.71 × 10−6; GAATC, OR = 0.4, P = 1.16 × 10−4). All individuals with the GAATC haplotype also carried the HLA class II DRB1*0701 allele. In a separate analysis, the DRB1*0701 allele was associated with a decreased risk of NSHL (OR = 0.5, 95% confidence interval = 0.4, 0.7). These data support the importance of the HLA class II region in NSHL etiology.